Sign In
Buy HKMPY
$44.37
+0 (+0%)
At Close: Jul 31, 2026
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets
Hikma acquires Novugen's FDA-approved ANDA for trametinib
01:10pm, Thursday, 17'th Apr 2025
LONDON , April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application
Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript)
07:03pm, Wednesday, 26'th Feb 2025
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2024 Results Conference Call February 26, 2025 2:00 AM ET Company Participants Riad Mishlawi - Chief Executive Officer Khalid Nabilsi - Chief Financial Offic
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
07:41am, Tuesday, 14'th Jan 2025
LONDON , Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergen
LONDON, Aug. 20, 2024 /PRNewswire/ -- Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep.
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
03:18pm, Thursday, 15'th Aug 2024
LONDON , Aug. 15, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg fr
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript
08:10pm, Friday, 09'th Aug 2024
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2024 Pre-Recorded Presentation August 8, 2024 2:30 AM ET Company Participants Riad Mishlawi - CEO & Director Khalid Nabilsi - CFO Riad Mishlawi Thank you for
Hikma Pharmaceuticals rallies following bullish first-half earnings
03:44am, Thursday, 08'th Aug 2024
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares bounced 7.6% higher on Thursday following publication of its half-year financial report. “We had an excellent first half of the year.
Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript
12:33pm, Thursday, 22'nd Feb 2024
Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
01:20pm, Wednesday, 21'st Feb 2024
Continues Hikma and the Office of National Drug Control Policy effort to combat the opioid overdose epidemic in the US COLUMBUS, Ohio , Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma),
Hikma announces US launch of COMBOGESIC® IV
07:00am, Monday, 05'th Feb 2024
Offers health care providers a new multimodal approach to adult pain management LONDON , Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, ann
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
12:34pm, Thursday, 01'st Feb 2024
A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims that they helped
U.K. Dividend Stocks Portfolio: 2023 Year-End Review
03:48am, Tuesday, 09'th Jan 2024
U.K. Dividend Stocks Portfolio: 2023 Year-End Review
Hikma Pharmaceuticals upgrades guidance for all segments except injectables
06:26am, Thursday, 02'nd Nov 2023
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has upgraded its full-year guidance for two out of three of its business segments following “good momentum” in the first half, but lowered annual sal
